HC Wainwright Has Bearish Estimate for DYN FY2024 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Dyne Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($3.55) per share for the year, down from their previous estimate of ($3.06). HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25).

A number of other equities analysts have also issued reports on DYN. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Stifel Nicolaus upped their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Piper Sandler reissued an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Stock Down 6.3 %

Shares of NASDAQ DYN opened at $28.39 on Monday. Dyne Therapeutics has a 12 month low of $9.76 and a 12 month high of $47.45. The company has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10. The business’s 50 day moving average is $32.48 and its two-hundred day moving average is $35.24.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the third quarter valued at about $36,000. US Bancorp DE grew its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $62,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. The trade was a 1.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.